Skip to main content
SpringerLink
Log in

Subepidermal Bullous Dermatoses

  • Chapter
  • First Online:
Hospital-Based Dermatopathology

  • 1056 Accesses

Abstract

The autoimmune bullous dermatoses discussed in this chapter are the consequence of defects at or near the basement membrane zone. At the light microscopy level, the subepidermal bullous dermatoses can generally be classified based upon the predominant type of inflammatory cells within the blister space: cell-poor, eosinophils, neutrophils, or lymphocytes. The pauci-inflammatory group includes epidermolysis bullosa (EB) and porphyria cutanea tarda. Using transmission electron microscopy, EB are further classified into four major types (EB simplex, junctional EB, dystrophic EB, and Kindler syndrome) according to the plane of the cleavage. Entities with predominance of eosinophils within the blister space include bullous pemphigoid, mucous membrane pemphigoid/cicatricial pemphigoid, and pemphigoid gestationis. Those containing mainly neutrophils are linear IgA disease, anti-laminin gamma-1 pemphigoid, epidermolysis bullosa acquisita, bullous lupus erythematosus, and dermatitis herpetiformis. Lymphocytes are prominent in lichen planus pemphigoid. Due to overlapping histologic features, direct immunofluorescence (DIF) studies are necessary to distinguish various entities. Of those with similar DIF findings, indirect immunofluorescence (IIF) studies performed on sodium chloride split skin are essential to determine the location of the antigens. In the setting of similar IIF findings as noted in EBA and anti-laminin gamma-1 pemphigoid, immunoblot is needed to confirm the diagnosis.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 249.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Fine JD. Inherited epidermolysis bullosa. Orphanet J Rare Dis. 2010;5:12. https://doi.org/10.1186/1750-1172-5-12.

    Article  PubMed  PubMed Central  Google Scholar 

  2. Has C, Nystrom A, Saeidian AH, Bruckner-Tuderman L, Uitto J. Epidermolysis bullosa: molecular pathology of connective tissue components in the cutaneous basement membrane zone. Matrix Biol. 2018;71–72:313–329.

    Google Scholar 

  3. Fine JD, Bruckner-Tuderman L, Eady RAJ, Bauer EA, Bauer JW, et al. Inherited epidermolysis bullosa: updated recommendations on diagnosis and classification. J Am Acad Dermatol. 2014;70(6):1103–26.

    Article  PubMed  Google Scholar 

  4. Laimer M, Prodinger C, Bauer JW. Hereditary epidermolysis bullosa. J Dtsch Dermatol Ges. 2015;13(11):1125–33.

    PubMed  Google Scholar 

  5. Uitto J, Has C, Vahidnezhad H, Youssefian L, Bruckner-Tuderman L. Molecular pathology of the basement membrane zone in heritable blistering diseases: the paradigm of epidermolysis bullosa. Matrix Biol. 2017;57–58:76–85.

    Google Scholar 

  6. Küttner V, Mack C, Rigbolt KT, et al. Global remodelling of cellular microenvironment due to loss of collagen VII. Mol Syst Biol. 2013;9:657. https://doi.org/10.1038/msb.2013.17.

    Article  PubMed  PubMed Central  Google Scholar 

  7. Has C, Castiglia D, del Rio M, et al. Kindler syndrome: extension of FERMT1 mutational spectrum and natural history. Hum Mutat. 2011;32(11):1204–12.

    Article  CAS  PubMed  Google Scholar 

  8. Bauer JW, Schaeppi H, Kaserer C, Hantich B, Hintner H. Large melanocytic nevi in hereditary epidermolysis bullosa. J Am Acad Dermatol. 2001;44(4):577–84.

    Article  CAS  PubMed  Google Scholar 

  9. Lanschuetzer CM, Laimer M, Nischler E, Hintner H. Epidermolysis bullosa nevi. Dermatol Clin. 2010;28(1):179–83.

    Article  CAS  PubMed  Google Scholar 

  10. Melo JN, Teruya PY, Machado MC, Valente NS, Sotto MN, Oliveira ZN. Epidermolysis bullosa nevi: clinical, dermatoscopical and histological features in a case of recessive dystrophic form. An Bras Dermatol. 2011;86(4):743–6.

    Article  PubMed  Google Scholar 

  11. Hintner H, Stingl G, Schuler G, Fritsch P, Stanley J, Katz S, Wolff K. Immunofluorescence mapping of antigenic determinants within the dermal epidermal junction in mechanobullous diseases. J Invest Dermatol. 1981;76(2):113–8.

    Article  CAS  PubMed  Google Scholar 

  12. Singal AK. Porphyria cutanea tarda: recent update. Mol Genet Metab. 2019. pii: S1096-7192(18)30579-1.

    Google Scholar 

  13. Bygum A, Brandrup F. Iron overload in porphyria cutanea tarda. Br J Dermatol. 2000;143(5):1116.

    Article  CAS  PubMed  Google Scholar 

  14. Miura K, Taura K, Kodama K, et al. Hepatitis C virus-induced oxidative stress suppresses hepcidin expression through increased histone deacetylase activity. Hepatology. 2008;8(5):1420–9.

    Article  CAS  Google Scholar 

  15. Schulenburg-Brand D, Katugampola R, Anstey AV, Badminton MN. The cutaneous porphyrias. Dermatol Clin. 2014;32(3):369–84.

    Article  CAS  PubMed  Google Scholar 

  16. Wissel SP, Sordillo P, Anderson KE, Sassa S, Savillo RL, Kappas A. Porphyria cutanea tarda associated with the acquired immune deficiency syndrome. Am J Hematol. 1987;25(1):107–13.

    Article  CAS  PubMed  Google Scholar 

  17. Aguilera P, Laguno M, To-Figueras J. Human immunodeficiency virus and risk of porphyria cutanea tarda: a possible association examined in a large hospital. Photodermatol Photoimmunol Photomed. 2016;32(2):93–7.

    Article  CAS  PubMed  Google Scholar 

  18. Becker FT. Porphyria cutanea tarda induced by estrogens. Arch Dermatol. 1965;92:252–6.

    Article  PubMed  Google Scholar 

  19. Horner ME, Alikhan A, Tintle S, Tortorelli S, Davis DM, Hand JL. Cutaneous porphyrias part I: epidemiology, pathogenesis, presentation, diagnosis, and histopathology. Int J Dermatol. 2013;52(12):1464–80.

    Article  PubMed  Google Scholar 

  20. Zaborowski AG, Paulson GH, Peters AL. Sight threatening complications in porphyria cutanea tarda. Eye (Lond). 2004;18(9):949–50.

    Article  CAS  Google Scholar 

  21. Lambrecht RW, Thapar M, Bonkovsky HL. Genetic aspects of porphyria cutanea tarda. Semin Liver Dis. 2007;27(1):99–108.

    Article  CAS  PubMed  Google Scholar 

  22. Fevang SA, Kroon S, Skadberg O. Pseudoporphyria or porphyria cutanea tarda? Diagnostic and treatment difficulties. Acta Derm Venereol. 2008;88(4):426–7.

    PubMed  Google Scholar 

  23. Amber KT, Murrell DF, Schmidt E, Joly P, Borradori L. Autoimmune subepidermal bullous diseases of the skin and mucosae: clinical features, diagnosis, and management. Clin Rev Allergy Immunol. 2018;54(1):26–51.

    Article  PubMed  Google Scholar 

  24. Schmidt E, Zillikens D. Pemphigoid diseases. Lancet. 2013;381(9863):320–32.

    Article  PubMed  Google Scholar 

  25. Zakka LR, Reche P, Ahmed AR. Role of MHC class II genes in the pathogenesis of pemphigoid. Autoimmun Rev. 2011;11(1):40–7.

    Article  CAS  PubMed  Google Scholar 

  26. Arechalde A, Braun RP, Calza AM, Hertl M, Didierjean L, Saurat JH, Borradori L. Childhood bullous pemphigoid associated with IgA antibodies against BP180 or BP230 antigens. Br J Dermatol. 1999;140(1):112–8.

    Article  CAS  PubMed  Google Scholar 

  27. Lamberts A, Meijer JM, Jonkman MF. Nonbullous pemphigoid: a systematic review. J Am Acad Dermatol. 2018;78(5):989–95.

    Article  PubMed  Google Scholar 

  28. Pietkiewicz P, Gornowicz-Porowska J, Bowszyc-Dmochowska M, Bartkiewicz P, Dmochowski M. Bullous pemphigoid and neurodegenerative diseases: a study in a setting of a central European university dermatology department. Aging Clin Exp Res. 2016;28(4):659–63.

    Article  PubMed  Google Scholar 

  29. Cugno M, Marzano AV, Bucciarelli P, Balice Y, Cianchini G, et al. Increased risk of venous thromboembolism in patients with bullous pemphigoid. The INVENTEP (INcidence of VENous ThromboEmbolism in bullous pemphigoid) study. Thromb Haemost. 2016;115(1):193–9.

    Article  PubMed  Google Scholar 

  30. Phoon YW, Fook-Chong SM, Koh HY, Thirumoorthy T, Pang SM, Lee HY. Infectious complications in bullous pemphigoid: an analysis of risk factors. J Am Acad Dermatol. 2015;72(5):834–9.

    Article  PubMed  Google Scholar 

  31. Hodge BD, Roach J, Reserva JL, Patel T, Googe A, Schulmeier J, Brodell RT. The spectrum of histopathologic findings in pemphigoid: avoiding diagnostic pitfalls. J Cutan Pathol. 2018;45(11):831–8.

    Article  PubMed  Google Scholar 

  32. Lehman JS, Carnilleri MJ. Diagnostic utility of direct immunofluorescence findings around hair follicles and sweat glands in immunobullous disease. J Cutan Pathol. 2013;40(2):230–5.

    Article  PubMed  Google Scholar 

  33. Villani AP, Chouvet B, Kanitakis J. Application of C4d immunohistochemistry on routinely processed tissue sections for the diagnosis of autoimmune bullous dermatoses. Am J Dermatopathol. 2016;38(3):186–8.

    Article  PubMed  Google Scholar 

  34. Pfaltz K, Mertz K, Rose C, Scheidegger P, Pfaltz M, Kempf W. C3d immunohistochemistry on formalin-fixed tissue is a valuable tool in the diagnosis of bullous pemphigoid of the skin. J Cutan Pathol. 2010;37(6):654–8.

    Article  PubMed  Google Scholar 

  35. Cizenski JD, Michel P, Watson IT, Frieder J, Wilder EG, Wright JM, Menter MA. Spectrum of orocutaneous disease associations. Immune-mediated conditions. J Am Acad Dermatol. 2017;77(5):795–806.

    Article  PubMed  Google Scholar 

  36. Leverkus M, Bhol K, Hirako Y, Pas H, Sitaru C, Baier G, et al. Cicatricial pemphigoid with circulating autoantibodies to beta4 integrin, bullous pemphigoid 180 and bullous pemphigoid 230. Br J Dermatol. 2001;145(6):998–1004.

    Article  CAS  PubMed  Google Scholar 

  37. Rose C, Schmidt E, Kerstan A, Thoma-Uszynski S, Wesselmann U, Käsbohrer U, Zillikens D, Shimanovich I. Histopathology of anti-laminin 5 mucous membrane pemphigoid. J Am Acad Dermatol. 2009;61(3):433–40.

    Article  CAS  PubMed  Google Scholar 

  38. Xu HH, Werth VP, Parisi E, Sollecito TP. Mucous membrane pemphigoid. Dent Clin N Am. 2013;57(4):611–30.

    Article  PubMed  Google Scholar 

  39. Rashid KA, Gurcan HM, Ahmed AR. Antigen specificity in subsets of mucous membrane pemphigoid. J Invest Dermatol. 2006;126(12):2631–6.

    Article  CAS  PubMed  Google Scholar 

  40. Egan CA, Lazarova Z, Darling TN, et al. Anti-epiligrin cicatricial pemphigoid and relative risk for cancer. Lancet. 2001;357(9271):1850–1.

    Article  CAS  PubMed  Google Scholar 

  41. Setterfield J, Shirlaw PJ, Kerr-Muir M, et al. Mucous membrane pemphigoid: a dual circulating antibody response with IgG and IgA signified a more severe and persistent disease. Br J Dermatol. 1998;138(4):602–10.

    Article  CAS  PubMed  Google Scholar 

  42. Vassileva S, Drenovska K, Manuelyan K. Autoimmune blistering dermatoses as systemic diseases. Clin Dermatol. 2014;32(3):364–75.

    Article  PubMed  Google Scholar 

  43. Daito J, Katoh N, Asai J, et al. Brunsting-Perry cicatricial pemphigoid associated with autoantibodies to the C-terminal domain of BP180. Br J Dermatol. 2008;159(4):984–6.

    Article  CAS  PubMed  Google Scholar 

  44. Mehra T, Guenova E, Dechent F, et al. Diagnostic relevance of direct immunofluorescence in ocular mucous membrane pemphigoid. J Dtsch Dermatol Ges. 2015;13(12):1268–74.

    PubMed  Google Scholar 

  45. Maderal AD, Lee Salisbury P 3rd, Jorizzo JL. Desquamative gingivitis: diagnosis and treatment. J Am Acad Dermatol. 2018;78(5):851–61.

    Article  PubMed  Google Scholar 

  46. Lipozencic J, Ljubojevic S, Bukvic-Mokos Z. Pemphigoid gestationis. Clin Dermatol. 2012;30(1):51–5.

    Article  PubMed  Google Scholar 

  47. Semkova K, Black M. Pemphigoid gestationis: current insights into pathogenesis and treatment. Eur J Obstet Gynecol Reprod Biol. 2009;145(2):138–44.

    Article  PubMed  Google Scholar 

  48. Kridin K. Subepidermal autoimmune bullous diseases: overview, epidemiology, and associations. Immunol Res. 2018;66(1):6–17.

    Article  PubMed  Google Scholar 

  49. Kwon EJ, Ntiamoah P, Shulman KJ. The utility of C4d immunohistochemistry on formalin-fixed paraffin-embedded tissue in the distinction of polymorphic eruption of pregnancy from pemphigoid gestationis. Am J Dermatopathol. 2013;35(8):787–91.

    Article  PubMed  Google Scholar 

  50. Sävervall C, Sand FL, Thomsen SF. Pemphigoid gestationis: current perspectives. Clin Cosmet Investig Dermatol. 2017;10:441–9.

    Article  PubMed  PubMed Central  Google Scholar 

  51. Fortuna G, Marinkovich MP. Linear immunoglobulin A bullous dermatosis. Clin Dermatol. 2012;30(1):38–50.

    Article  PubMed  Google Scholar 

  52. Tsuchisaka A, Ohara K, Ishii N, Nguyen NT, Marinkovich MP, Hashimoto T. Type VII collagen is the major autoantigen for sublamina densa-type linear IgA bullous dermatosis. J Invest Dermatol. 2015;135(2):626–9.

    Article  CAS  PubMed  Google Scholar 

  53. Ishiko A, Shimizu H, Masunaga T, Yancey KB, Giudice GJ, Zone JJ, et al. 97 kDa linear IgA bullous dermatosis antigen localizes in the lamina lucida between the NC16A and carboxyl terminal domains of the 180 kDa bullous pemphigoid antigen. J Invest Dermatol. 1998;111(1):93–6.

    Article  CAS  PubMed  Google Scholar 

  54. Paul C, Wolkenstein P, Prost C, Caux F, Rostoker G, et al. Drug-induced linear IgA disease: target antigens are heterogeneous. Br J Dermatol. 1997;136(3):406–11.

    Article  CAS  PubMed  Google Scholar 

  55. Selvaraj PK, Khasawneh FA. Linear IgA bullous dermatosis: a rare side effect of vancomycin. Ann Saudi Med. 2013;33(4):397–9.

    Article  PubMed  PubMed Central  Google Scholar 

  56. Chanal J, Ingen-Housz-Oro S, Ortonne N, Duong TA, Thomas M, et al. Linear IgA bullous dermatosis: comparison between the drug-induced and spontaneous forms. Br J Dermatol. 2013;169(5):1041–8.

    Article  CAS  PubMed  Google Scholar 

  57. Kelly SE, Frith PA, Millard PR, et al. A clinicopathological study of mucosal involvement in linear IgA disease. Br J Dermatol. 1988;119(2):161–70.

    Article  CAS  PubMed  Google Scholar 

  58. Gotlieb J, Ingen-Housz-Oro S, Alexandre M, Grootenboer-Mignot S, Aucouturier F, et al. Idiopathic linear IgA bullous demratosis: prognostic factors based on a case series of 71 adults. Br J Dermatol. 2017;177(1):212–22.

    Article  CAS  Google Scholar 

  59. Bernett CN, Rosario-Collazo JA. Linear IGA dermatosis. StatPearls [Internet]. Treasure Island: StatPearls Publishing; 2018.

    Google Scholar 

  60. El-Domyati M, Abdel-Wahab H, Ahmad H. Immunohistochemical localization of basement membrane laminin 5 and collagen IV in adult linear IgA disease. Int J Dermatol. 2015;54(8):922–8.

    Article  CAS  PubMed  Google Scholar 

  61. Garel B, Ingen-Housz-Oro S, Afriat D, Prost-Squarcioni C, Tetart F, et al. Drug-induced linear immunoglobulin A bullous dermatosis: a French retrospective pharmacovigilance study of 69 cases. Br J Clin Pharmacol. 2018; https://doi.org/10.1111/bcp.13827.

  62. Shimanovich I, Hirako Y, Sitaru C, et al. The autoantigen of anti-p200 pemphigoid is an acidic noncollagenous N-linked glycoprotein of the cutaneous basement membrane. J Invest Dermatol. 2003;121(6):1402–8.

    Article  CAS  PubMed  Google Scholar 

  63. Dainichi T, Kurono S, Ohyama B, et al. Anti-laminin gamma-1 pemphigoid. Proc Natl Acad Sci U S A. 2009;106(8):2800–5.

    Article  PubMed  PubMed Central  Google Scholar 

  64. Dilling A, Rose C, Hashimoto T, Zillikens D, Shimanovich I. Anti-p200 pemphigoid: A novel autoimmune subepidermal blistering disease. J Dermatol. 2007;34(1):1–8.

    Article  PubMed  Google Scholar 

  65. Meijer JM, Diercks GF, Schmidt E, Pas HH, Jonkman MF. Laboratory diagnosis and clinical profile of anti-p200 pemphigoid. JAMA Dermatol. 2016;152(6):897–904.

    Article  PubMed  Google Scholar 

  66. Commin MH, Schmidt E, Duvert-Lehembre S, Lasek A, Morice C, et al. Clinical and immunological features and outcome of anti-p200 pemphigoid. Br J Dermatol. 2016;175(4):776–81.

    Article  CAS  PubMed  Google Scholar 

  67. Ohata C, Ishii N, Koga H, Fukuda S, Tateishi C, et al. Coexistence of autoimmune bullous diseases (AIBDs) and psoriasis: a series of 145 cases. J Am Acad Dermatol. 2015;73(1):50–5.

    Article  PubMed  Google Scholar 

  68. Goetze S, Dumke AK, Zillikens D, Hipler UC, Elsner P. Anti-p200/laminin gamma-1 pemphigoid associated with metastatic oesophageal cancer. J Eur Acad Dermatol Venereol. 2017;31(4):e219–21.

    Article  CAS  PubMed  Google Scholar 

  69. Hayashi M, Okamura K, Uijie H, Iwata H, Suzuki T. Case of anti-p200 pemphigoid accompanying uterine malignancy. J Dermatol. 2018;45(12):e341–2.

    Article  PubMed  Google Scholar 

  70. Rose C, Weyers W, Denisjuk N, Hillen U, Zillikens D, Shimanovich I. Histopathology of anti-p200 pemphigoid. Am J Dermatopathol. 2007;29(2):119–24.

    Article  PubMed  Google Scholar 

  71. Woodley DT, Briggaman RA, O’Keefe EJ, Inman AO, Queen LL, Gammon WR. Identification of the skin basement- membrane autoantigen in epidermolysis bullosa acquisita. N Engl J Med. 1984;310(16):1007–13.

    Article  CAS  PubMed  Google Scholar 

  72. Hubner F, Recke A, Zillikens D, Linder R, Schmidt E. Prevalence and age distribution of pemphigus and pemphigoid diseases in Germany. J Invest Dermatol. 2016;136(12):2495–8. https://doi.org/10.1016/j.jid.2016.07.013.

    Article  CAS  PubMed  Google Scholar 

  73. Koga H, Prost-Squarcioni C, Iwata H, Konkman MF, Ludwig J, Bieber K. Epidermolysis bullosa acquisita: the 2019 update. Front Med. 2019;5:362. https://doi.org/10.3389/fmed.2018.00362.

    Article  Google Scholar 

  74. Prost-Squarcioni C, Caux F, Schmidt E, Jonkman MF, Vassileva S, et al. International Bullous Diseases Group: consensus on diagnostic criteria for epidermolysis bullosa acquisita. Br J Dermatol. 2018;179(1):30–41.

    Article  CAS  PubMed  Google Scholar 

  75. Vodegel RM, Jonkman MF, Pas HH, de Jong MC. U-serrated immunodeposition pattern differentiates type VII collagen targeting bullous diseases from other subepidermal bullous autoimmune diseases. Br J Dermatol. 2004;151(1):112–8.

    Article  CAS  PubMed  Google Scholar 

  76. Terra JB, Meijer JM, Jonkman MF, Diercks GF. The n- vs. u-serration is a learnable criterion to differentiate pemphigoid from epidermolysis bullosa acquisita in direct immunofluorescence serration pattern analysis. Br J Dermatol. 2013;169(1):100–5.

    Article  CAS  PubMed  Google Scholar 

  77. Meijer JM, Atefi I, Diercks GFH, Vorobyev A, Zuiderveen J, et al. Serration pattern analysis for differentiating epidermolysis bullosa acquisita from other pemphigoid diseases. J Am Acad Dermatol. 2018;78(4):754–759.e6.

    Article  PubMed  Google Scholar 

  78. Sebaratnam DF, Murrell DF. Bullous systemic lupus erythematosus. Dermatol Clin. 2011;29(4):649–53.

    Article  CAS  PubMed  Google Scholar 

  79. Chanprapaph K, Sawatwarakul S, Vachiramon V. A 12-year retrospective review of bullous systemic lupus erythematosus in cutaneous and systemic lupus erythematosus patients. Lupus. 2017;26(12):1278–84.

    Article  CAS  PubMed  Google Scholar 

  80. Pons-Estel GJ, Quintana R, Alarcon GS, Sacnun M, Ugarte-Gil MF, et al. A 12-year retrospective review of bullous systemic lupus erythematosus in cutaneous and systemic lupus erythematosus patients. Lupus. 2018;27(10):1753–4.

    Article  CAS  PubMed  Google Scholar 

  81. Chen M, Marinkovich P, Veis A. Interactions of the amino-terminal non-collagenous (NC1) domain of type VII collagen with extracellular matrix proteins. J Biol Chem. 1997;272(23):14516–22.

    Article  CAS  PubMed  Google Scholar 

  82. Chan LS, Lapiere JC, Chen M, et al. Bullous systemic lupus erythematosus with autoantibodies recognizing multiple skin basement membrane components, bullous pemphigoid antigen 1, laminin-5, laminin-6 and type VII collagen. Arch Dermatol. 1999;135(5):569–73.

    Article  CAS  PubMed  Google Scholar 

  83. Fujimoto W, Hamada T, Yamada J, Matsuura H, Iwatsuki K. Bullous systemic lupus erythematosus as an initial manifestation of SLE. J Dermatol. 2005;32(12):1021–7.

    Article  PubMed  Google Scholar 

  84. De Risi-Pugliese T, Aubart FC, Haroche J, Moguelet P, Grootenboer-Mignot S, et al. Clinical, histological, immunological presentations and outcomes of bullous systemic lupus erythematosus: 10 new cases and a literature review of 118 cases. Semin Arthris Rheum. 2018;48(1):83–9.

    Article  Google Scholar 

  85. Nico MM, Lourenço SV. Multiple blisters along the lip vermilion are a clue to bullous lupus erythematosus. Acta Derm Venereol. 2012;92(4):404–5.

    Article  PubMed  Google Scholar 

  86. Vassileva S. Bullous systemic lupus erythematosus. Clin Dermatol. 2004;22(2):129–38.

    Article  PubMed  Google Scholar 

  87. Sardy M, Karpati S, Peterfy F, Rasky K, Tomsits E, et al. Comparison of a tissue transglutaminase ELISA with the endomysium antibody test in the diagnosis of gluten-sensitive enteropathy. Z Gastroenterol. 2000;38(5):357–64.

    Article  CAS  PubMed  Google Scholar 

  88. Cardones AR, Hall RP 3rd. Pathophysiology of dermatitis herpetiformis: a model for cutaneous manifestations of gastrointestinal inflammation. Immunol Allergy Clin N Am. 2012;32(2):263–74.

    Article  Google Scholar 

  89. Mobacken H, Kastrup W, Nilsson LA. Incidence and prevalence of dermatitis herpetiformis in western Sweden. Acta Derm Venereol. 1984;64(5):400–4.

    CAS  PubMed  Google Scholar 

  90. Fry L. Dermatitis herpetiformis: problems, progress and prospects. Eur J Dermatol. 2002;12(6):523–31.

    PubMed  Google Scholar 

  91. Rose C, Armbruster FP, Ruppert J, Igl BW, Zillikens D, Shimanovich I. Autoantibodies against epidermal transglutaminase are a sensitive diagnostic marker in patients with dermatitis herpetiformis on a normal or gluten-free diet. J Am Acad Dermatol. 2009;61:39–43.

    Article  CAS  PubMed  Google Scholar 

  92. Mendes FB, Hissa-Elian A, Abreu MA, Gonçalves VS. Review: dermatitis herpetiformis. An Bras Dermatol. 2013;88(4):594–9.

    Article  PubMed  PubMed Central  Google Scholar 

  93. Caproni M, Antiga E, Melani L, Fabbri P, Italian Group for Cutaneous Immunopathology. Guidelines for the diagnosis and treatment of dermatitis herpetiformis. J Eur Acad Dermatol Venereol. 2009;23(6):633–8.

    Article  CAS  PubMed  Google Scholar 

  94. Lara-Corrales I, Pope E. Autoimmune blistering diseases in children. Semin Cutan Med Surg. 2010;29(2):85–91.

    Article  CAS  PubMed  Google Scholar 

  95. Collin P, Salmi TT, Hervonen K, Kaukinen K, Reunala T. Dermatitis herpetiformis: a cutaneous manifestation of coeliac disease. Ann Med. 2017;49(1):23–31.

    Article  CAS  PubMed  Google Scholar 

  96. Bolotin D, Petronic-Rosic V. Dermatitis herpetiformis. Part II. Diagnosis, management, and prognosis. J Am Acad Dermatol. 2011;64(6):1027–33.

    Article  PubMed  Google Scholar 

  97. Barnadas MA. Dermatitis herpetiformis: a review of direct immunofluorescence findings. Am J Dermatopathol. 2016;38(4):283–8.

    Article  PubMed  Google Scholar 

  98. Dieterich W, Laag E, Bruckner-Tuderman L, Reunala T, Kárpáti S, et al. Antibodies to tissue transglutaminase as serologic markers in patients with dermatitis herpetiformis. J Invest Dermatol. 1999;113(1):133–6.

    Article  CAS  PubMed  Google Scholar 

  99. Zaraa I, Mahfoudh A, Sellami MK, Chelly I, El Euch D, et al. Lichen planus pemphigoides: four new cases and a review of the literature. Int J Dermatol. 2013;52(4):406–12.

    Article  PubMed  Google Scholar 

  100. Bouloc A, Vignon-Pennamen MD, Caux F, Teillac D, Wechsler J, et al. Lichen planus pemphigoides is a heterogeneous disease: a report of five cases studied by immunoelectron microscopy. Br J Dermatol. 1998;138(6):972–80.

    Article  CAS  PubMed  Google Scholar 

  101. Yoon KH, Kim SC, Kang DS, Lee IJ. Lichen planus pemphigoides with circulating autoantibodies against 200 and 180 kDa epidermal antigens. Eur J Dermatol. 2000;10(3):212–4.

    CAS  PubMed  Google Scholar 

  102. Zillikens D, Caux F, Mascaro JM, et al. Autoantibodies in lichen planus pemphigoides react with a novel epitope within the C-terminal NC16A domain of BP180. J Invest Dermatol. 1999;113(1):117–21.

    Article  CAS  PubMed  Google Scholar 

  103. Mignogna MD, Fortuna G, Leuci S, Stasio L, Mezza E, Ruoppo E. Lichen planus pemphigoides, a possible example of epitope spreading. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2010;109(6):837–43.

    Article  PubMed  Google Scholar 

  104. Schmidgen MI, Butsch F, Schadmand-Fischer S, Steinbrink K, Grabbe S, et al. Pembrolizumab-induced lichen planus pemphigoides in a patient with metastatic melanoma. J Disch Dermatol Ges. 2017;15(7):742–5.

    Google Scholar 

  105. Jang SH, Yun SJ, Lee SC, Lee JB. Lichen planus pemphigoides associated with chronic hepatitis B virus infection. Clin Exp Dermatol. 2015;40(8):868–71.

    Article  CAS  PubMed  Google Scholar 

  106. Sultan A, Stojanov IJ, Lerman MA, Kabani S, Haber J, Freedman J, Woo SB. Oral lichen planus pemphigoides: a series of four cases. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2015;120(1):58–68.

    Article  Google Scholar 

  107. Solomon LW, Helm TN, Stevens C, Neiders ME, Kumar V. Clinical and immunopathologic findings in oral lichen planus pemphigoides. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2007;103(6):808–13.

    Article  PubMed  Google Scholar 

  108. Schwieger-Briel A, Moellmann C, Mattulat B, Schauer F, Kiritsi D, Schmidt E, et al. Bullous pemphigoid in infants: characteristics, diagnosis and treatment. Orphanet J Rare Dis. 2014;9:185. https://doi.org/10.1186/s13023-014-0185-6.

    Article  PubMed  PubMed Central  Google Scholar 

  109. Bisherwal K, Pandhi D, Singal A, Sharma S. Infantile bullous pemphigoid following vaccination. Indian Pediatr. 2016;53(5):425–6.

    Article  PubMed  Google Scholar 

  110. Baykal C, Okan G, Sarica R. Childhood bullous pemphigoid developed after the first vaccination. J Am Acad Dermatol. 2001;44(2 Suppl):348–50.

    Article  CAS  PubMed  Google Scholar 

  111. De la Fuente S, Hernandez-Martin A, de Lucas R, Gonzalez-Ensenat MA, Vicente A, et al. Postvaccination bullous pemphigoid in infancy: report of three new cases and literature review. Pediatr Dermatol. 2013;30(6):741–4.

    Article  PubMed  Google Scholar 

  112. Reis-Filho EG, Silva Tde A, Aguirre LH, Reis CM. Bullous pemphigoid in a 3-month-old infant: case report and literature review of this dermatosis in childhood. An Bras Dermatol. 2013;88(6):961–5.

    Article  PubMed  PubMed Central  Google Scholar 

  113. McGrath JA, Schofield OM, Eady RA. Epidermolysis bullosa pruriginosa: dystrophic epidermolysis bullosa with distinctive clinicopathological features. Br J Dermatol. 1994;130(5):617–25.

    Article  CAS  PubMed  Google Scholar 

  114. Christiano AM, Greenspan DS, Lee S, et al. Cloning of human type VII collagen. Complete primary sequence of the alpha 1 (VII) chain and identification of intragenic polymorphisms. J Biol Chem. 1994;269(32):20256–62.

    CAS  PubMed  Google Scholar 

  115. Kim WB, Alavi A, Pope E, Walsh S. Epidermolysis bullosa pruriginosa: case series and review of the literature. Int J Low Extrem Wounds. 2015;14(2):196–9.

    Article  CAS  PubMed  Google Scholar 

  116. Mellerio JE, Ashton GH, Mohammedi R, Lyon CC, Kirby B, et al. Allelic heterogeneity of dominant and recessive COL7A1 mutations underlying epidermolysis bullosa pruriginosa. J Invest Dermatol. 1999;112(6):984–7.

    Article  CAS  PubMed  Google Scholar 

  117. Hayashi M, Kawaguchi M, Hozumi Y, Nakano H, Sawamura D, Suzuki T. Dystrophic epidermolysis bullosa pruriginosa of elderly onset. J Dermatol. 2011;38(2):173–8.

    Article  CAS  PubMed  Google Scholar 

  118. Fernandes JD, Gabbi TV, Vilela MA, Sotto MN, Criado PR, Romiti R. Blisters on the legs. Clin Exp Dermatol. 2008;33(1):81–2.

    Article  CAS  PubMed  Google Scholar 

  119. Morimoto N, Shimizu A, Hattori M, Kuriyama Y, Nakano H, Ohnishi K. Dystrophic epidermolysis bullosa pruriginosa presenting with flagellate scarring lesions. Clin Exp Dermatol. 2019;44(2):e5–6.

    Article  CAS  PubMed  Google Scholar 

  120. Nakamura E, Majima Y, Hashizume H, Tokura Y, Nakano H. Dominant dystrophic epidermolysis bullosa pruriginosa with a COL7A1 exon 87 c.6898C>T mutation. Clin Exp Dermatol. 2019;44(1):82–4.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Dermatology, Faculty of Medicine of the University of São Paulo, São Paulo, SP, Brazil

    Mirian Nacagami Sotto

  2. Department of Pathology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA

    Mai P. Hoang

Authors
  1. Mirian Nacagami Sotto
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mai P. Hoang
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Mirian Nacagami Sotto .

Editor information

Editors and Affiliations

  1. Professor of Pathology, Harvard Medical School, Director of Dermatopathology, Massachusetts General Hospital, Boston, MA, USA

    Mai P. Hoang

  2. Professor of Pathology and Dermatology, Director, Dermatopathology Unit, Duke University Medical Center, Durham, NC, USA

    Maria Angelica Selim

Rights and permissions

Reprints and permissions

Copyright information

© 2020 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Sotto, M.N., Hoang, M.P. (2020). Subepidermal Bullous Dermatoses. In: Hoang, M., Selim, M. (eds) Hospital-Based Dermatopathology. Springer, Cham. https://doi.org/10.1007/978-3-030-35820-4_10

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-35820-4_10

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-35819-8

  • Online ISBN: 978-3-030-35820-4

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation